Weill Cornell Medicine‘s monogenic diseases therapy developer Lexeo Therapeutics has made its public debut with $85m in series A financing.

Lexeo Therapeutics, a US-based gene therapy developer founded out of Weill Cornell Medicine, has emerged from stealth with an oversubscribed $85m series A round co-led by healthcare-focused venture capital firm Longitude Capital and investment firm Omega Funds. Pharmaceutical firm Lundbeck and life sciences real estate investment firm Alexandria Real Estate Equities participated through their subsidiaries…

The rest of this content is only accessible to University Venturing: News, Data, and Events - Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.